DPP-4 and GLP-1: How Peptide Cleavage Changes the Signal
Understand how DPP-4 processes native GLP-1, why intact and total measurements differ, and how enzyme resistance is distinct from receptor activation or storage stability.
| Enzyme | Dipeptidyl peptidase-4, also written DPP-IV |
|---|---|
| Research substrate | Native GLP-1 forms |
| Key event | N-terminal processing changes the measured peptide species |
| Assay distinction | Intact peptide versus total immunoreactive material |
| Design distinction | Enzyme resistance and receptor activity require separate evidence |
| Hero product | Hero SM |
Research on DPP-4 and GLP-1 explains one reason a peptide signal can change quickly even when related material remains detectable. DPP-4 is an enzyme that can process the beginning of native GLP-1. The resulting molecular form is different from the starting signal.
This matters for both biology and measurement. An assay that tracks intact peptide may tell a different story from one detecting several related forms. It also explains why making an analog resistant to an enzyme is a different task from showing receptor activation.
Origin story: identifying the disappearing signal
Mentlein and colleagues studied DPP-IV processing of peptides including GLP-1 and GIP. Their enzyme and human-serum experiments helped connect a defined cleavage reaction with the disappearance of the original peptide forms (Mentlein et al., 1993).
Deacon and colleagues then examined GLP-1 degradation in human plasma in vitro and identified an N-terminally truncated form that was also a major endogenous metabolite. This linked laboratory processing with material detected in biological samples (Deacon et al., 1995).
The discovery was about molecular identity over time, not simply a falling concentration. If the starting species becomes another species, a measurement needs enough specificity to distinguish them before assigning a biological interpretation.
How DPP-4 changes native GLP-1
For the commonly discussed amidated form, processing changes GLP-1(7-36)amide into GLP-1(9-36)amide. The numbering identifies the peptide segment. Removing the initial two residues changes the molecule rather than merely reducing the number of identical copies present (Mentlein et al., 1993; Deacon et al., 1995).
The important experimental distinction is between the intact starting peptide and its processed product. The two should not be treated as interchangeable GLP-1 receptor agonist inputs. A report should identify which form was prepared and which form the assay detected.
Two research strategies follow different questions. Enzyme inhibition asks what changes when processing is reduced. Analog design asks whether a modified molecule resists processing while retaining other required properties. Neither result can be assumed from the other.
Semaglutide’s discovery program included a design intended to resist DPP-4 degradation alongside an albumin-binding strategy. The changes were investigated as part of a complete molecule, rather than presented as a rule that every enzyme-resistant peptide has the same exposure or activity (Lau et al., 2015).
Key studies: intact, processed, and total are different measurements
| Measurement or experiment | Question | Important boundary |
|---|---|---|
| Intact GLP-1 measurement | How much starting intact form is detected? | Depends on the method’s specificity |
| Metabolite measurement | How much processed form is detected? | Not the same analyte as intact GLP-1 |
| Total immunoreactive measurement | How much material reacts with the assay? | Recognition depends on the assay and peptide forms |
| Enzyme-resistance experiment | Does the material persist under defined processing conditions? | Does not establish receptor potency or shelf life |
The early degradation studies support separating the analytes. They do not mean that every assay labeled GLP-1 measures the same mixture. Read the method’s recognition and calibration details before comparing results across reports (Mentlein et al., 1993; Deacon et al., 1995).
A simple hypothetical example shows the problem. If intact material falls while processed material rises, an assay recognizing both may show less change than an intact-specific assay. The apparently conflicting observations can reflect different measurement questions.
Likewise, preserving a sample after collection is different from preventing processing inside the original biological system. Sample handling can affect the material that reaches the instrument. The record should distinguish collection conditions from the physiological question.
For research summaries, write the peptide form, specimen or system, time interval, and readout beside the result. This small amount of detail prevents a phrase such as GLP-1 increased from hiding an unresolved identity question.
Weak spots: what we don’t know
Resistance to one enzyme is not resistance to every clearance or degradation pathway. A molecule can avoid one processing event while remaining subject to other biological processes. Its overall exposure needs direct measurement.
A truncated product also should not be called universally inactive without specifying the endpoint. Loss of the starting peptide’s intended receptor behavior does not establish the absence of every possible effect in every system.
The half-life guide explains why persistence and effect are separate. Enzyme-resistance evidence also does not establish the stability of a research stock under its storage conditions.
As of November 5, 2026, FDA-approved medicines containing semaglutide exist. That product status does not validate a supplier-branded research material, and a mechanistic discussion of DPP-4 does not establish equivalence to an approved formulation (FDA, 2021).
Handling DPP-4 and GLP-1 questions in the lab
Record the exact peptide identity and distinguish an intact substrate from a processed product or engineered analog. Include the analytical method and the forms it detects. A generic GLP-1 entry is often too broad for interpreting processing experiments.
For preparation math, a nominal 5 mg research sample recovered at a final volume of 2 mL gives 2.5 mg/mL, or 2,500 mcg/mL. A 0.10 mL analytical aliquot initially contains a nominal 250 mcg.
If a reaction changes the species present, that starting mass calculation does not reveal the later intact concentration. The original peptide and products need appropriate measurements. Keep initial preparation inputs separate from reaction results.
The reconstitution guide and calculator support arithmetic. The testing guide explains why method selectivity and molecular identity matter when interpreting a result.
DPP-4 and GLP-1 FAQ
Does DPP-4 processing leave the peptide unchanged?
No. The reaction produces a different molecular form.
Do intact and total GLP-1 assays measure the same thing?
Not necessarily. Their recognition of the starting peptide and related forms can differ.
Does enzyme resistance establish vial shelf life?
No. Biological processing and stored-solution stability require different evidence.
What is Hero SM?
Hero SM is Hero Peptides’ semaglutide research material, listed in 5 mg and 10 mg vials. It should be identified separately from native GLP-1 and its processed forms.
References
- Mentlein R, et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829-835. Source.
- Deacon CF, et al. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952-957. Source.
- Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. Source.
- U.S. Food and Drug Administration. Wegovy (semaglutide), NDA 215256, approval review. 2021. Source.
For laboratory research use only. Not for human or veterinary use. This article summarizes published research and is not medical advice.